Farxiga Shortage: What Providers and Prescribers Need to Know in 2026

For clinicians managing patients on Farxiga (dapagliflozin), 2026 brings both good news and new complexities. This briefing covers the current availability landscape, the implications of the first generic dapagliflozin approval, common access barriers your patients are encountering, and practical clinical recommendations.

Current Availability: No FDA-Listed Shortage, But Access Is Not Universal

As of 2026, Farxiga is not listed on the FDA Drug Shortages database. AstraZeneca's manufacturing supply for dapagliflozin has remained stable. However, patients are frequently reporting access difficulties due to a convergence of factors: expanding indications increasing overall demand, heightened prior authorization requirements, step therapy policies, and variable pharmacy inventory — particularly at smaller or lower-volume pharmacies.

Providers should be aware that even patients with insurance may experience prescription lag of several days to weeks while prior authorization is processed — a clinically significant delay for patients managing heart failure, CKD, or poorly controlled T2DM.

Clinical Significance: The April 2026 Generic Dapagliflozin Approval

On April 7, 2026, the FDA approved the first generic versions of dapagliflozin tablets from multiple manufacturers. These generics carry the same prescribing information, contraindications, warnings, and precautions as brand-name Farxiga. They are bioequivalent and therapeutically equivalent per FDA standards.

The approved indications for generic dapagliflozin include:

Adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged ≥10 years with type 2 diabetes mellitus

Reduce the risk of hospitalization for heart failure in adults with T2DM with established CVD or multiple CV risk factors

Note: The generic approval at this time covers T2DM and HF risk reduction indications. For the CKD indication, brand-name Farxiga remains the reference. Verify formulary status with your patient's specific insurance plan when prescribing for CKD.

Insurance Access Barriers Providers Should Know

The most common insurance barriers your patients will encounter with Farxiga in 2026:

Step therapy requiring Jardiance first: Many UHC, Aetna, and commercial plans require a 30-day trial of empagliflozin before approving dapagliflozin. Document clinical rationale for Farxiga specifically when submitting the PA — e.g., CKD indication, DAPA-CKD data, patient's response history.

Prior authorization for CKD indication: Many plans require documented eGFR values, urine albumin-to-creatinine ratio (UACR), and documentation that an ACE inhibitor or ARB was tried. Ensure your PA submission includes these labs.

Medicare Part D negotiations: Farxiga was selected in the first cycle of Medicare drug price negotiations (2024). Coverage and copay structures may be changing across Part D plans in 2026 — advise Medicare patients to confirm their current coverage and copay.

Formulary tier changes: With generic competition, some plans are moving brand Farxiga to higher tiers while adding generic dapagliflozin at a lower tier. Patients may see unexpected copay increases if they insist on brand.

Clinical Considerations for Switching Within Class

When access barriers necessitate switching, consider the following:

Farxiga → Jardiance (empagliflozin): Clinically reasonable for T2DM, HF, and CKD. No washout period required. Jardiance has FDA approval for all three indications. Start at standard initiation dose (10 mg daily for HF/CKD; 10-25 mg for T2DM).

Farxiga → Invokana (canagliflozin): Appropriate for T2DM and CKD (with T2DM). Exercise caution in patients with peripheral artery disease, history of amputation, or peripheral neuropathy due to Invokana's boxed warning for lower limb amputation risk.

Farxiga → Steglatro (ertugliflozin): Only appropriate for T2DM indication. Not FDA-approved for HF or CKD. Limited cardiovascular outcome data compared to other SGLT2 inhibitors.

Monitoring Considerations When Initiating or Continuing Farxiga

Regardless of access challenges, ensure patients on dapagliflozin are appropriately monitored:

eGFR: Not recommended for glycemic control if eGFR <45 mL/min/1.73m². Can continue for HF/CKD indications at lower eGFR thresholds with individual clinical assessment.

Volume depletion: Evaluate and correct volume depletion before initiating, especially in elderly patients or those on loop diuretics

DKA risk: Hold dapagliflozin for at least 3 days before major surgery or prolonged fasting. Counsel patients on ketoacidosis symptoms.

Genital mycotic infections: Counsel patients, especially women, on hygiene and early reporting of symptoms

How Providers Can Help Patients Access Farxiga

Practical steps to reduce access delays for your patients:

Write for generic dapagliflozin (or do not write 'dispense as written') to allow pharmacy substitution and lower insurance tier placement.

Submit PA proactively when prescribing Farxiga for CKD or HF indications — don't wait for a rejection.

Recommend the SavingsRx Card for commercially insured patients: pay as little as $0/month (max $175 savings). farxiga.com or 1-855-332-7944.

Refer patients to medfinder if they're struggling to locate the medication at a local pharmacy. medfinder.com/providers offers a provider-facing resource to help your patients track down in-stock pharmacies efficiently.

For a step-by-step provider workflow, read our companion guide: How to help your patients find Farxiga in stock: a provider's guide.